Cargando…
A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia
Acute myelogenous leukaemia (AML) is associated with risk factors that are largely unknown and with a heterogeneous response to treatment. Here, we provide a comprehensive quantitative understanding of AML proteomic heterogeneities and hallmarks by using the AML proteome atlas, a proteomics database...
Autores principales: | Hu, C. W., Qiu, Y., Ligeralde, A., Raybon, A.Y., Yoo, S. Y., Coombes, K. R., Qutub, A. A., Kornblau, S. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051028/ https://www.ncbi.nlm.nih.gov/pubmed/30988472 http://dx.doi.org/10.1038/s41551-019-0387-2 |
Ejemplares similares
-
Immunotherapy for Acute Myelogenous Leukaemia
por: Powles, R. L., et al.
Publicado: (1973) -
Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia
por: Lee, C-Y, et al.
Publicado: (2007) -
Myelogenic Leukaemia
Publicado: (1915) -
Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells
por: Kornblau, Steven M., et al.
Publicado: (2013) -
Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
por: Zuhrie, S. R., et al.
Publicado: (1980)